Skip to main content

Table 1 Demographic and clinical characteristics of NMOSD and HC

From: Increased serum IL-36β and IL-36γ levels in patients with neuromyelitis optica spectrum disorders: association with disease activity

 

NMOSD(50)

HC (30)

P

Gender, n (% female)

48(98%)

27(90%)

0.358

Age at sampling, years

46.46 ± 15.04

51.30 ± 12.71

0.144

Age at onset, years

41.9 ± 15.71

Follow-up duration, years

4.66 ± 4.33

Annualized relapse rate (ARR)

2.24 ± 0.97

EDSS at nadir

3.98 ± 2.12

Presentation at sampling, n (%)

 ON

7(14%)

 Area postrema syndrome

2(4%)

 AM

26(52%)

 Brain stem syndrome

6(12%)

 Diencephalic clinical syndrome

3(6%)

 Cerebral syndrome

6(12%)

 length of newly identified spinal cord lesion (vertebral segments)

5(1, 15)

 AQP4-Ab, n (%)

28(56%)

 Imunossupressive agents and dosage, n (%)

 Prednisonlone (12 mg/d)

5(10%)

 Azathioprine (2 mg/kg.d)

8(16%)

 Mycophenolate Mofetil(1.5 g/d)

7(14%)

 Rituximaba

30(60%)

  1. Abbreviations: NMOSD neuromyelitis optica spectrum disorders, HC healthy control, ARR annualized relapse rate, EDSS Kurtzke Expanded Disability Status Scale, ON optica neuritis, AM acute myelitis
  2. a: All patients were treated with rituximab (Biogen-Idec, Cambridge,MA, and Genentech, San Francisco, CA) 100 mg (equivalent of 50–59 mg/m2) IV, one infusion per week for 3 consecutive weeks. Continued dosage was dependent on the percentage of circulating CD19+ B-cell counts. Whenever it reached 1% of total lymphocyte population, rituximab 100 mg was reinfused